Prodrug strategies for paclitaxel

Ziyuan Meng; Quanxia Lv; Jun Lu; Houzong Yao; Xiaoqing Lv; Feng Jiang; Aiping Lyu; Ge Zhang

doi:10.3390/ijms17050796

Prodrug strategies for paclitaxel

Ziyuan Meng, Quanxia Lv, Jun Lu, Houzong Yao, Xiaoqing Lv, Feng Jiang^*, Aiping Lyu, Ge Zhang

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

79 Citations (Scopus)

47 Downloads (Pure)

Abstract

Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective.

Original language	English
Article number	796
Journal	International Journal of Molecular Sciences
Volume	17
Issue number	5
DOIs	https://doi.org/10.3390/ijms17050796
Publication status	Published - May 2016

User-Defined Keywords

Low selectivity
Paclitaxel
Poor water solubility
Prodrug

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms17050796

Full TextFinal published version, 1.67 MB

Cite this

@article{3dd415d2c8794f8ab69121f9b4e94470,

title = "Prodrug strategies for paclitaxel",

abstract = "Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective.",

keywords = "Low selectivity, Paclitaxel, Poor water solubility, Prodrug",

author = "Ziyuan Meng and Quanxia Lv and Jun Lu and Houzong Yao and Xiaoqing Lv and Feng Jiang and Aiping Lyu and Ge Zhang",

year = "2016",

month = may,

doi = "10.3390/ijms17050796",

language = "English",

volume = "17",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "MDPI",

number = "5",

}

TY - JOUR

T1 - Prodrug strategies for paclitaxel

AU - Meng, Ziyuan

AU - Lv, Quanxia

AU - Lu, Jun

AU - Yao, Houzong

AU - Lv, Xiaoqing

AU - Jiang, Feng

AU - Lyu, Aiping

AU - Zhang, Ge

PY - 2016/5

Y1 - 2016/5

N2 - Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective.

AB - Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from all over the world. In this review, we discuss the different strategies especially prodrug strategies that are currently used to make paclitaxel more effective.

KW - Low selectivity

KW - Paclitaxel

KW - Poor water solubility

KW - Prodrug

UR - http://www.scopus.com/inward/record.url?scp=84969677939&partnerID=8YFLogxK

U2 - 10.3390/ijms17050796

DO - 10.3390/ijms17050796

M3 - Review article

C2 - 27223283

AN - SCOPUS:84969677939

SN - 1661-6596

VL - 17

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 5

M1 - 796

ER -

Prodrug strategies for paclitaxel

Abstract

User-Defined Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this